Datos del Documento


Por favor, use este identificador para citar o enlazar este documento: https://ria.asturias.es/RIA/handle/123456789/6787
Registro de Metadatos Completo
Campo Dublin Core Valor Idioma
dc.contributor.authorEspina Fernández, Marta-
dc.contributor.authorSierra Zapico, Luisa María-
dc.contributor.authorBlanco González, Elisa-
dc.contributor.authorAmes, Tyler-
dc.contributor.authorMontes Bayón, María-
dc.contributor.authorSanz Medel, Alfredo-
dc.date.accessioned2016-06-29T09:14:23Z-
dc.date.available2016-06-29T09:14:23Z-
dc.date.issued2015-09-06-
dc.identifier.citationBiochemical Pharmacology 98 (2015) 69–77eng
dc.identifier.otherDOI: 10.1016/j.bcp.2015.08.112-
dc.identifier.urihttps://ria.asturias.es/RIA/handle/123456789/6787-
dc.description.abstractThe use of Pt-containing compounds as chemotherapeutic agents facilitates drug monitoring by using highly sensitive elemental techniques like inductively coupled plasma mass spectrometry (ICP-MS). However, methodological problems arise when trying to compare different experiments due to the high variability of biological parameters. In this work we have attempted to identify and correct such variations in order to compare the biological behavior of cisplatin, oxaliplatin and pyrodach-2 (a novel platinum-containing agent). A detailed study to address differential cellular uptake has been conducted in three different cell lines: lung adenocarcinoma (A549); cisplatin-sensitive ovarian carcinoma (A2780); and cisplatin-resistant ovarian carcinoma (A2780cis). The normalization of Pt results to cell mass, after freeze-drying, has been used to minimize the errors associated with cell counting. Similarly, Pt accumulation in DNA has been evaluated by referencing the Pt results to the DNA concentration, as measured by 31P monitoring using flow-injection and ICP-MS detection. These strategies have permitted to address significantly lower Pt levels in the resistant cells when treated with cisplatin or oxaliplatin as well as an independent behaviour from the cell type (sensitive or resistant) for pyrodach-2. Similarly, different levels of incorporation in DNA have been found for the three drugs depending on the cell model revealing a different behavior regarding cell cisplatin resistance. Further speciation experiments (by using complementary HPLC–ICP-MS and HPLC–ESI-Q-TOF MS) have shown that the main target in DNA is still the N7 of the guanine but with different kinetics of the ligand exchange mechanism for each of the compounds under evaluation.eng
dc.description.sponsorshipPhosplatin Therapeutics Ministerio de Economía (CTQ2013-49032-C2-1-R) FICYT (FC-15-GRUPIN14-010) FICYT (Contrato predoctoral Severo Ochoa BP13114)eng
dc.language.isoengeng
dc.publisherElseviereng
dc.relation.ispartofBiochemical Pharmacologyeng
dc.relation.haspart98eng
dc.relation.isreferencedbyNo, esta versión no ha sido citadaeng
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/deed.eseng
dc.source69;77-
dc.subjectCisplatineng
dc.subjectOxaliplatineng
dc.subjectPyrodach-2eng
dc.subjectCell lineseng
dc.subjectICP-MSeng
dc.subjectDNAeng
dc.subjectAdduct formationeng
dc.subject.classificationPublicadoeng
dc.titleQuantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: Comparison of different Pt-containing drugseng
dc.typearticleeng
Aparece en las colecciones: Open Access DRIVERset
Química

Archivos en este documento:
Fichero Tamaño Formato  
Archivo.pdf1.01 MBAdobe PDFVer/Abrir
Mostrar el registro Básico


Ver estadísticas del documento


Este documento está sujeto a una licencia Creative Commons: Licencia Creative Commons Creative Commons